Concentration of Gelatinases and Their Tissue Inhibitors in Pancreatic Inflammatory and Neoplastic Tumors and Their Influence on the Early Postoperative Course

• Authors: Andrzej Lekstan , Marek Olakowski , Beata Jabłońska , Krzysztof Łabuzek , Edyta Olakowska , Ines Filip , Paweł Lampe
• Languages of publication: EN

Abstracts

EN

Pancreatic cancer (PC) is the fourth leading cause of death in the world, due to neoplastic disease. Chronic pancreatitis (CP) is a progressive disease leading towards pancreatic fibrosis. The aim of the study was to assess the impact of matrix metalloproteinases 2 and 9 (MMP2 and 9) and their tissue inhibitor (TIMP 1 and 2) concentrations in case of PC and CP tissue homogenates on early treatment results of patients subject to pancreatic resections. Material and methods. The study group comprised 63 patients, including 25 (39.68%) female and 38 (60.32%) male patients. Group 1 (CP) consisted of 31 patients with CP (F: M = 10/21). Group 2 (PC) consisted of 32 patients with PC (F: M = 15:17). The pancreatic tumor samples were collected from the resected pancreas, being subject to electrophoresis and immunoenzymatic studies. After confirming their activity, MMP2, MMP9, TIMP1, TIMP2 concentrations were determined. Correlation analysis of MMPs and TIMPs concentrations was performed in relation to the following: tumor diameter, age, BMI, hospitalization, duration of symptoms and surgery, blood loss, incidence of perioperative complications. Results. Group differences were presented in terms of: age, BMI, ASA, duration of symptoms, jaundice, tumor diameter, time of operation. There were no differences considering weight loss, blood loss, extent of resection, and hospitalization. Significant MMPs and TIMPs concentration differences between groups were demonstrated. Conclusions. Comparison of PC to CP tissue samples showed significantly higher levels of metalloproteinases and TIMPs in the former. Positive correlations of MMP1, TIMP1 and 2 with tumor diameter (CP) were observed, and MMP2 with the duration of surgery and blood loss (PC). There was no MMPs and TIMPs concentration levels influence on the incidence of postoperative complications.

Keywords

EN

pancreatic cancer; chronic pancreatitis; metalloproteinases; tissue inhibitors of metalloproteinases; gelatinases

• Publisher: De Gruyter Open
• Journal: Polish Journal of Surgery
• Year: 2013
• Volume: 85
• Issue: 2
• Pages: 65-72

Dates

published

1 - 02 - 2013

online

22 - 03 - 2013

Contributors

author

Andrzej Lekstan

• Department of Gastrointestinal Surgery, Medical University of Silesia in Katowice

author

Marek Olakowski

• Department of Gastrointestinal Surgery, Medical University of Silesia in Katowice

author

Beata Jabłońska

• Department of Gastrointestinal Surgery, Medical University of Silesia in Katowice

author

Krzysztof Łabuzek

• Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia in Katowice

author

Edyta Olakowska

• Department of Physiology, Medical University of Silesia in Katowice

author

Ines Filip

• Department of Anesthesiology, Medical University of Silesia in Katowice

author

Paweł Lampe

• Department of Anesthesiology, Medical University of Silesia in Katowice

References

• 1. Herszényi L, Tulassay Z: Epidemiology of gastrointestinal and liver tumors. Eur Rev Med PharmacolSci 2010; 14: 249-58.
• 2. Spanier BW, Dijkgraaf MG, Bruno MJ: Epidemiology, aetiology and outcome of acute and chronic pancreatitis: An update. Best Pract Res Clin Gastroenterol 2008; 22: 45-63.[Crossref][WoS]
• 3. Łukaszewicz M, Mroczko B. Szmitkowski M: Rola metaloproteinaz i ich inhibitorów w raku trzustki. Postepy Hig Med Dośw 2008; 62: 141-47.
• 4. Gress TM, Muller- Pillasch F, Lerch MM et al.: Expression and in situ localization of genes encoding for extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995; 62:407-13.[Crossref]
• 5. Bloomston M, Zervos ED , Rosemurgy ASII : Matrix Metalloproteinases and Their Role in Pancreatic Cancer: A Review of Preclinical Studies and Clinical Trials. Ann Surg Oncol 2002; 9: 668-74.[Crossref][PubMed]
• 6. Maisonneuve P, Lowenfels AB: Epidemiology of pancreatic cancer: an update. Dig Dis 2010; 28: 645-56.[Crossref]
• 7. Krejs GJ: Pancreatic cancer: epidemiology and risk factors. Dig Dis 2010; 28: 355-58.[Crossref][WoS][PubMed]
• 8. Pezzilli R: Etiology of chronic pancreatitis: has it changed in the last decade? World J Gastroenterol 2009; 15: 4737-40.[PubMed][WoS][Crossref]
• 9. Otsuki M: Chronic pancreatitis in Japan: epidemiology, prognosis, diagnostic criteria, and future problems. J Gastroenterol 2003; 38: 315-26.[Crossref][PubMed]
• 10. EyigorC, Karaca B, Kuzeyli-Yildirim Y et al.: Does the tumor localization in advanced pancreatic cancer have an influence on the management of symptoms and pain? J BUON 2010; 15: 543-46.
• 11. Eshuis WJ, van der Gaag NA , Rauws EA et al.: Therapeutic delay and survival after surgery for cancer of the pancreatic head with or without preoperative biliary drainage. Ann Surg 2010; 252: 840-49.
• 12. Braganza JM, Lee SH , McCloy RF et al.: Chronic pancreatitis. Lancet 2011; 377: 1184-97.[WoS]
• 13. Kimura W: Strategies for the treatment of invasive ductal carcinoma of the pancreas and how to achieve zero mortality for pancreaticoduodenectomy. J HepatobiliaryPancreat Surg 2008; 15: 270-77.
• 14. Müller MW, Friess H, Kleeff J et al.: Middle segmental pancreatic resection: An option to treat benign pancreatic body lesions. Ann Surg 2006; 24: 909-18.
• 15. Hildebrand P, Dudertadt S, Czymek R et al.: Different surgical strategies for chronic pancreatitis significantly improve long-term outcome: a comparative single center study. Eur J Med Res 2010; 15: 351-56.[WoS][Crossref]
• 16. King JC , Abeywardina S, Farrell JJ et al.: A modern review of the operative management of chronic pancreatitis. Am Surg 2010; 76: 1071-74.[PubMed]
• 17. Frey CF , Amikura K: Local resection of the head of the pancreas combined with longitudinal pancreaticojejunostomy in the management of patients with chronic pancreatitis. Ann Surg 1994; 220: 92.
• 18. Brown KM, Tompkins AJ , Yong S et al.: Pancreaticoduodenectomy is curative in the majority of patients with node-negative ampullary cancer. Arch Surg 2005; 140: 529-32.[Crossref]
• 19. Cameron JL , Riall TS , Coleman J et al.: One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006; 244: 10-15.
• 20. Behrman SW, Rush BT, Dilawari RA : A modern analysis of morbidity after pancreatic resection. Am Surg 2004; 70: 675-82.[PubMed]
• 21. Winter JM, Cameron JL , Campbell KA et al.: 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J GastrointestSurg 2006; 10: 1199-10.[Crossref]
• 22. Talar-Wojnarowska R, Gasiorowska A, StrzelczykJ et al.: Prognostic factors in the operative and palliative treatment of pancreatic cancer. Neoplasma 2003; 50: 383-87.
• 23. Koshiba T, Hosotani R, Wada M et al.: Detection of matrix metalloproteinase activity in human pancreatic cancer. Surg Today 1997; 27: 302-04.[Crossref]
• 24. Mroczko B, Lukaszewicz-Zajac M, Wereszczynska-Siemiatkowska U et al.: Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. Pancreas 2009; 38: 613-18.[WoS][Crossref]
• 25. Ellenrieder V, Alber B, Lacher U et al.: Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer 2000; 85: 14-20.
• 26. Yokoyama M, Ochi K, Ichimura M et al.: Matrix metalloproteinase-2 in pancreatic juice for diagnosis of pancreatic cancer. Pancreas 2002; 24: 344-47.
• 27. Stumpf M, Klinge U, Wilms A et al.: Changes of the extracellular matrix as a risk factor for anastomotic leakage after large bowel surgery. Surgery 2005; 137: 229-34.

Identifiers

DOI

10.2478/pjs-2013-0012